Product
IOV-4001
1 clinical trial
4 indications
Indication
melanomaIndication
Metastatic MelanomaIndication
Stage III Non-small Cell Lung CancerIndication
NSCLCClinical trial
A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-06-01